Balsammedica Sp. z o.o.

Warsaw 11 trials 7 recruiting

11 Registered trials

7 Currently recruiting

Organisation

Balsammedica Sp. z o.o.

Location

Warsaw, Poland

Identifier

ORG-100050916

Address

Ul. Goleszowska 1/U5, 01-249, Poland

Departments

5706: balsamMedica - Centrum Medyczne
Balsammedica Sp
N/A
NA
Practice
Private Practice

Clinical trials at this site (11)

Search interface

A Multicenter, Open-Label, Dose Escalation Study of the Safety, Tolerability, and Efficacy of Budiodarone for the Treatment of Subjects with… Pending

2025-523860-19-00 Non-permanent Atrial Fibrillation 10
ZENITH: Zilebesiran in Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk … Recruiting

2025-522960-34-00 Established cardiovascular disease 5 2026-02-09
EASi-PROTKT™ - A study to test vicadrostat (BI 690517) taken together with empagliflozin in people with type 2 diabetes, high blood pressure… Recruiting

2025-521188-11-00 Type 2 diabetes 5 2025-10-15
A study to test whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure and a weak pumping functio… Recruiting

2024-519525-38-00 Heart failure 5 2025-08-22
A phase III, randomized, open-label, blinded endpoint, comparative trial of ferric derisomaltose versus no intravenous iron in iron-deficien… Recruiting

2024-519059-28-00 Chronic Heart Failure 5 2025-07-17
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction Recruiting

2024-519219-32-00 Heart Failure With Reduced Ejection Fraction 5 2025-06-23
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Trial Evaluating the Efficacy and Safety of RBD5044 in Patients with… Recruiting

2023-510369-92-00 Mixed Dyslipidemia 4 2025-01-28
A study to test whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure. Recruiting

2023-509706-30-00 Heart failure (HF) 5 2024-10-18
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening);… Ended

2024-519000-27-00 Hypertension 5 2025-07-17
A Phase IIb Two-Cohort, Randomised, Placebo controlled, Double blind, Multi-centre, Dose-ranging Study of AZD5462 in Stable Patients with Ch… Ended

2023-510148-19-00 Chronic Heart Failure 4 2024-07-03
A Study of LY3540378 in Participants with Worsening Chronic Heart Failure with Preserved Ejection Fraction (HFpEF) Ended

2023-505902-40-00 Heart Failure with Preserved Ejection Fraction 4 2023-03-28